1-5 of 5
Keywords: Prothrombin complex concentrates
Close
Sort by
Journal Articles
Journal Articles
Subject Area:
Hematology , Oncology
Acta Haematol (1995) 94 (Suppl. 1): 2–7.
Published Online: 18 February 2009
...Inge Scharrer Thromboembolic complications of prothrombin complex concentrate (PCC) therapy were first reported by Kasper in 1973 [N Engl J Med 1973;289:160]. The following contaminants were discussed as possible contributors to the thrombogenicity risk: the presence of other zymogens in PCCs...
Journal Articles
Subject Area:
Hematology , Oncology
Acta Haematol (1995) 94 (Suppl. 1): 8–11.
Published Online: 18 February 2009
... properties evaluated. The results were compared with those for two prothrombin complex concentrates (PCCs): Preconativ (Kabi Pharmacia) and Prothromplex TIM4 (Immuno). The measured values for factor IX coagulant activity (FIX:C) generally agreed with the manufacturers’ labeled values. The purified...
Journal Articles
Subject Area:
Hematology , Oncology
Acta Haematol (1995) 94 (Suppl. 1): 18–24.
Published Online: 18 February 2009
...I. MacGregor; L. McLaughlin; O. Drummond; C. Prowse; J. Ferguson The thrombogenicity of prothrombin complex concentrates (PCCs) has been known as a risk factor since their first clinical use about 30 years ago. The development of in vivo models to define the thrombogenic components in PCCs...
Journal Articles
Subject Area:
Hematology , Oncology
Acta Haematol (1995) 94 (Suppl. 1): 53–58.
Published Online: 18 February 2009
...Gilbert C. White II Prothrombin complex concentrates (PCCs) have been used for the treatment of hemorrhagic episodes in patients with hemophilia B but have been associated with a high incidence of thrombotic complications. Newer, ultrapure concentrates of factor IX contain less extraneous proteins...